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RESUMO 
A Leucemia mieloide aguda (LMA) é um tipo de cancro que ocorre nas células 
hematopoiéticas da linhagem mieloide, devido a alterações malignas no processo 
normal de hematopoiese na medula óssea (MO). Variadas alterações genéticas estão na 
origem do processo de transformação das células hematopoiéticas mielóides em células 
malignas, denominadas por blastos ou mieloblastos. Estas células sofrem uma paragem 
no ciclo celular e adquirem a capacidade de proliferar indefinidamente assim como a 
capacidade de resistência à apoptose, permanecendo num estado indiferenciado e 
extremamente proliferativo. A elevada proliferação de mieloblastos leva à sua 
acumulação na MO e posteriormente no sangue periférico, alterando a hematopoiese 
normal, o que leva a um défice na produção das células do sangue e consequentemente 
a desordens como trombocitopenia, anemia ou granulocitopenia. Um dos maiores 
desafios que esta patologia apresenta actualmente é a resistência à quimioterapia.  
Vários fatores têm sido indicados como relevantes na aquisição de resistência aos 
fármacos utilizados atualmente na terapia, por parte das células leucémicas. Neste 
trabalho é focada a família de factores de crescimento VEGF (Vascular Endothelial 
Growth Factors), nomeadamente o VEGF-C e o seu receptor VEGFR-3. Alguns sub-tipos 
de LMA expressam VEGFR-3 e produzem VEGF-C, estando colocada a hipótese da 
existência de um loop autócrino que estará a modelar a sobrevivência de células 
leucémicas. Inicialmente indicado como promotor de linfangiogénese durante o 
desenvolvimento embrionário, a sinalização do VEGF-C através do VEGFR-3 tem sido 
mais recentemente relacionada com a progressão e agressividade de vários tipos de 
cancro, estando ligada à proliferação, sobrevivência e consequente resistência a drogas 
citotóxicas pelas células de LMA. Estudos em LMA pediátrica estabeleceram que o 
aumento dos níveis de VEGF-C endógeno nas células leucémicas está relacionado com a 
diminuição da resposta aos fármacos, revelando uma influência do factor na 
sobrevivência destas células. Ao nível molecular, a sinalização de VEGF-C demonstrou 
induzir a expressão do factor anti-apóptotico Bcl-2, que está sobre expresso em variados 
tumores e está relacionado com o processo de tumorigénese e resistência à 
quimioterapia.  
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Adicionalmente, o colesterol intracelular tem demonstrado proteger células de 
LMA dos efeitos citotóxicos dos fármacos e estas células apresentam um metabolismo 
de colesterol desregulado, com aumento dos níveis de colesterol intracelular após 
exposição aos fármacos.  
A sinalização através do VEGFR-1 é mediada pelos níveis de colesterol intracelular 
em células de LMA, e elevados níveis de colesterol aumentam a activação deste 
receptor, contribuindo para a expansão e desenvolvimento da doença, o que sugere 
uma relação entre os níveis de colesterol celular e receptores da família VEGF. Uma vez 
que também o receptor VEGFR-3 está implicado na progressão de LMA, é importante 
compreender de que forma o colesterol celular estará a modelar a sua expressão, assim 
como de que forma poderá estar a modelar a produção do seu ligando VEGF-C, nas 
células leucémicas. A existência de uma modulação da produção de VEGF-C nas células 
pelo colesterol poderá sugerir um envolvimento deste na indução da expressão do 
factor anti-apóptotico Bcl-2 pelo VEGF-C, e subsequente resistência à quimioterapia.  
O objectivo do presente estudo passa por compreender de que forma o colesterol 
intracelular está a afectar a expressão dos factores VEGF-C, VEGFR-3 e Bcl-2 em células 
leucémicas, no sentido de compreender melhor a importância dos níveis de colesterol 
para estas células, e que relevância poderá ter para a actividade biológica destes 
factores. Como modelo de estudo para LMA foram utilizadas duas linhas celulares, HEL 
(Human Erythroleukemia) e THP-1 (Human Monocytic Leukemia), e a estratégia utilizada 
passou pelo enriquecimento e pela remoção parcial de colesterol destas células com 
complexos de colesterol + Metil-β-Ciclodextrina e Metil-β-Ciclodextrina, 
respectivamente. O tratamento das células com Metil-β-Ciclodextrina reduz a 
viabilidade das células e por isso foram utilizadas baixas concentrações (0.2 mM) 
durante períodos de tempo de 4 horas. Os níveis de colesterol das células foram sempre 
medidos após a exposição aos complexos de colesterol + Metil-β-Ciclodextrina e Metil-
β-Ciclodextrina para confirmar a eficiência do respectivo enriquecimento e parcial 
remoção. Os níveis de expressão de VEGFR-3, VEGF-C e Bcl-2 foram analisados nas duas 
condições de colesterol celular por PCR quantitativo (PCRq); os níveis de VEGF-C foram 
ainda analisados por Western-blotting e os de VEGFR-3 por citometria de fluxo.  
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Os resultados preliminares deste estudo demonstram que o enriquecimento das 
células leucémicas com colesterol promove a diminuição dos níveis de mRNA VEGFR-3, 
enquanto que a remoção parcial de colesterol promove um aumento dos níveis de 
mRNA do VEGF-C. Não foram detectadas diferenças na expressão de Bcl-2, o que 
demonstra que esta parece não ser afectada pelos níveis de colesterol celular. A 
expressão de VEGFR-3 através da análise por citometria de fluxo não demonstrou 
diferenças entre as duas condições de colesterol.  
Em suma, estes resultados demonstram um aumento do VEGF-C endógeno 
quando é removido colesterol das células leucémicas, indicando uma modelação da sua 
produção pelos níveis de colesterol celular. Os níveis de VEGFR-3 são afectados pelas 
alterações de colesterol apenas ao nível do mRNA, o que indica que a modelação de 
VEGFR-3 pelo colesterol é feita ao nível do mRNA. No entanto, são necessárias mais 
abordagens para compreender que funções celulares estão a ser modeladas pelas 
alterações de expressão verificadas, nomeadamente ensaios funcionais in vitro para 
analisar a proliferação celular e a resistência à apoptose, no sentido de investigar que 
relação poderá existir entre o que foi observado e a resistência à quimioterapia. Este 
trabalho deverá assim contribuir para uma melhor compreensão de como as vias de 
sinalização do VEGF-C são reguladas na leucemia. Uma vez que a expressão de VEGF-C 
tem sido associada à resistência à quimioterapia é importante explorar as questões 
obtidas neste estudo, para uma melhor compreensão de como as células de LMA 
resistem aos fármacos citotóxicos.  
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ABSTRACT 
Some subsets of Acute Myeloid Leukemia (AML) cells express the Vascular 
Endothelial Receptor 3 (VEGFR-3), a receptor for the Vascular Endothelial Growth 
Factor-C (VEGF-C). The VEGFR-3/VEGF-C axis has been related to many cancers, 
including leukemia, due to the promotion of cell proliferation, chemotherapy resistance 
and tumor aggressiveness. At the molecular level VEGF-C signaling has been shown to 
induce the expression of the Bcl-2 anti-apoptotic factor. Cholesterol has been reported 
to modulate the expression of VEGFR’s in AML. Here, we hypothesize that intracellular 
cholesterol levels could modulate signaling through the VEGFR-3/VEGF-C axis, 
contributing towards increased leukemia aggressiveness. To test this hypothesis we 
either enriched or partially depleted cholesterol from the THP-1 and HEL cell lines with 
Methyl-β-Cyclodextrin + cholesterol complexes and Methyl-β-Cyclodextrin alone, 
respectively. It was seen that Methyl-β-Cyclodextrin compromises cell viability, so we 
tested concentrations of 0,2 mM. In these conditions we looked at VEGFR-3, VEGF-C and 
Bcl-2 expression by RQ-PCR and Western Blot; VEGFR-3 expression was also assessed by 
flow cytometry. Our preliminary results show that cholesterol enrichment of cells leads 
to a decrease of VEGFR-3 mRNA levels, while cholesterol depletion leads to an increase 
of VEGF-C mRNA levels. No differences in Bcl-2 have been detected.  We are now 
confirming these results at the protein level. By flow cytometry VEGFR-3 expression 
didn’t show differences between conditions. Subsequent experiments will include in 
vitro functional assays to assess cell viability, proliferation and resistance to apoptosis. 
This work may contribute to better understand how VEGF-C signaling pathways are 
regulated in leukemia. As VEGF-C expression has been associated with resistance to 
chemotherapy by AML cells, this work may contribute to better understand how 
resistance is achieved.  
  
Key words: acute myeloid leukemia; cellular cholesterol; VEGF-C; VEGFR-3; 
chemotherapy resistance; Methyl-β-Cyclodextrin; Bcl-2; apoptosis 
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1.  HEMATOPOIESIS 
    1.1 Hematopoietic Process 
 
Hematopoiesis is a continuous process whereby the blood cells are formed 
and it takes place, in adulthood, mainly in the bone marrow (BM). The 
Hematopoietic Stem Cell (HSC) is the multipotent common precursor of all blood 
cells formed, making hematopoiesis a hierarchically organized process, starting 
with a precursor cell that will give rise to all lineages of hematopoietic cells. 
(Sashida and Iwama et al. 2012) (Seke Etet et al. 2013) et. al 2012)  
Hematopoietic Stem cells (HSCs) have the capacity of self-renewal and 
differentiation, giving rise to daughter stem cells to maintain the stem cell pool 
while still contributing to the pool of differentiating cells. Throughout the 
differentiation process these cells give rise to various intermediate progenitor cells 
that undergo a gradual commitment to each of the blood cell lineages, until a 
mature blood cell is formed (Doulatov et al. 2012). HSCs originate two major 
intermediate precursors which give rise to the two major hematopoietic cell 
lineages: myeloid and lymphoid. The lymphoid lineage yields T, B and NK (Natural 
Killer) lymphocytes and the myeloid lineage originates granulocytes (basophils, 
eosinophils, neutrophils), monocytes (dendritic cells and macrophage), 
erythroblasts (erythrocytes) and megakaryocytes (platelets) (Figure 1). 
As just mentioned HSCs reside at the apex of hematopoietic hierarchy and are 
modulated by different cellular and molecular mechanisms, to form mature blood 
cells. These comprise intrinsic genetic processes and bone marrow 
microenvironment derived factors. The interaction between blood cellsnd their 
microenvironment determines essential cellular processes such as proliferation, 
differentiation or apoptosis. (Doulatov et al. 2012) (C. Smith et al. 2003) 
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1.2 Malignant Hematopoiesis and Leukemia  
 
The regulated process of hematopoiesis can fail causing malignant 
transformation of blood forming cells. Normal hematopoietic progenitors can be 
transformed into malignant cells due to mutations in genes encoding critical 
regulatory pathways like the ones which regulate cell differentiation and 
maturation (Seke Etet et al. 2013). 
When a hematopoietic progenitor cell transforms into a malignant cell it 
acquires higher abilities of proliferation and survival, giving rise to a hematological 
neoplasm. Hematological malignancies can be derived from hematopoietic 
progenitors developing in the lymphoid or myeloid lineage or from multipotent 
hematopoietic stem cells (HSCs) (Lowenberg et al. 1999). 
Neoplastic proliferations of cells from the hematopoietic lineage may originate 
leukemias, which can be broadly divided into two main groups, according to the 
two major lineages that derive from the multipotent HSC: Lymphoid leukemias 
which affect B, T and NK lymphocytes lineage; and Myeloid leukemias which affect 
granulocytic, erythroid and megakaryocytic lineages (Estey et al. 2012).  
In addition to this simplified classification which results from the 
hematopoietic lineage affected, leukemia may also be further divided into acute 
leukemia or chronic leukemia, based on the rates of disease progression (acute 
leukemias progress from the BM to the peripheral blood in less time than chronic 
leukemias) and other molecular and cellular features (beyond the scope of the 
present Thesis) (Table 1).   
 
TABLE 1 – Four major types of Leukemia. A simplified view. 
Cell lineage Chronic Acute 
Myeloid Leukemia Chronic Myeloid Leukemia     Acute Myeloid Leukemia 
Lymphocytic Leukemia  Chronic lymphocytic Leukemia Chronic Myeloid Leukemia 
 
INTRODUCTION 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 – Schematic representation of hematopoiesis. This scheme represents, in a simplified 
manner, hematopoietic process steps during the generation of specific blood lineages from a 
common HSC. HSC can be broadly divided into two cellular subsets: LT-HSC (Long term HSC) and 
ST-HSC (Short term HSC). LT-HSC cells have the capacity to undergo self-renewal indefinitely, 
while ST-HSC have the capacity to undergo self-renewal. ST-HSC give rise to MPP (Multipotent 
Progenitors) which originate the two major blood cell lineages: Myeloid 
and Lymphoid derived from CMP (Common Myeloid Progenitors) and CLP (Common lymphoid 
progenitors), respectively. Dendritic cells may be originated both from myeloid and lymphoid 
lineages.  
 
INTRODUCTION 
 
5 
 
2. ACUTE MYELOID LEUKEMIA (AML) 
 
AML is a clonal hematopoietic disorder characterized by a group of genetic 
changes affecting a hematopoietic stem cell or a myeloid-specific progenitor cell. This 
changes lead to an undifferentiated and proliferative stage of myeloid cells, which 
become resistant to apoptosis. Cells which undergo cell cycle arrest and remain 
undifferentiated, instead of continuing the process of cell differentiation into a mature 
blood cell, are called blast cells. Higher proliferation and survival of blasts cells leads to 
their accumulation in the BM and expansion into the peripheral blood (Lowenberg et 
al. 1999).  
Blast cells are also found in healthy people, around five percent of the cells of a 
normal BM are blast cells, however, these cells do eventually continue to mature until 
becoming fully differentiated and functional, which does not occur in individuals with 
AML. Higher proliferation and survival of blasts cells leads to an accumulation in the 
bone marrow and peripheral blood. The blast percentage commonly used to diagnosis 
AML is around twenty percent in the peripheral blood and BM (Lowenberg et al. 
1999). 
The BM infiltration with blasts alters normal hematopoiesis, causing a decrease in 
the production of mature myeloid cells and therefore a decrease of these cells in 
peripheral blood, leading to thrombocytopenia, anemia, granulocytopenia and 
eventually serious infections and hemorrhage (Huang et al. 2013).  
AML can occur in patients of any age but is the most frequent type of leukemia in 
adults, having the lowest survival rate between all other sub-types and being primarily 
a disease of late adulthood. It is unusual a diagnosis of AML in patients younger than 
40 years old and usually the mean age of diagnosis is 65 years old (Deschler and 
Lübbert et al. 2006). The increased incidence of AML along aging is due largely to the 
existence of other hematopoietic disorders that can progress to leukemia, like 
myelodysplasic-related changes, which become more common in older patients 
(Lowenberg et al. 1999). To summarize, AML covers a heterogeneous group of myeloid 
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leukemias, which differ in the lineage that is affected, and also  the underlying cause, 
age of occurrence, and clinical prognosis.  
 
2.1 AML pathogenesis 
 
AML usually develops after an accumulation of specific mutations or 
translocations and other types of genetic alterations along time. These changes can be 
due to a variety of factors or an arrangement between those factors (Lowenberg et al. 
1999).  
There are several risk factors that can trigger leukemogenesis. These include age, 
prior hematological disorders, genetic disorders, exposures to viruses or chemical and 
radiation, as well as chemotherapy. These factors can alter in many ways, as referred, 
a hematopoietic progenitor cell line, triggering the  leukemogenesis process 
(Lowenberg et al. 1999) (Deschler and Lübbert et al.2006). 
Each sub-type of AML may have different casual agents and underlying 
mechanisms, suggesting that a particular molecular alteration or mutation may be 
caused by a particular agent, although in most cases AML is developed de novo, 
without evidence of exposure to any leukemogenic agent (Deschler and Lübbert et al. 
2006).  
 
2.2 AML diagnosis and classification  
 
As already mentioned AML is a heterogeneous disease and can be classified in 
several sub-types according to different parameters. This classification is part of the 
disease’s diagnosis and plays an important role in the decision of which treatment 
patient must be subjected to, and it is also an important predictor of disease’s 
prognosis.  
There are actually two major systems of AML classification based on four main 
methods of blast cells analysis: morphology, staining, molecular analysis and flow 
cytometry (see tables 2 and 3).  
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The French-American-British (FAB) system (Table 2) comprises the traditional 
classification of acute leukemia, based on morphologic characteristics and 
cytochemical studies of blast cells. The FAB system divides AML in 8 sub-types (M0 to 
M7) which differ according to the degree of maturation of leukemic blasts (Abdul-
hamid et al. 1999). 
 
 
TABLE 2 – French-American-British (FAB) classification system of AML. 
 
 M0 Undifferentiated acute myeloblastic leukemia 
M1 Acute myeloblastic leukemia with minimal differentiation 
M2 Acute myeloblastic leukemia with differentiation 
M3 Acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia 
M5 Acute monocytic leukemia  
M6 Acute erythroid leukemia 
M7 Acute megakaryoblastic leukemia 
 
Recently, with new and more advanced techniques of molecular analyses and with 
the principle that classification of leukemia should not only be based on morphologic 
means, the World Health Organization (WHO) created another classification system for 
AML. This is based more on the genetic heterogeneity of the disease (Table 3), 
attempting to clearly define blast cells and elucidate what specific issues are beyond 
their capacity of rapid and efficient replication (Vardiman et al. 2002) (Lowenberg et 
al.1999).  
The WHO system divides AML into 4 sub-groups: 1) AML with recurrent genetic 
abnormalities 2) AML with multi lineage dysplasia 3) therapy and myelodysplasic 
syndromes related AML 4) not otherwise categorized AML (this one reflects the FAB 
system classification M0 to M7) and corresponds to that cases where molecular 
genetics does not contribute to incorporate any of the other earlier (Lowenberg et 
al.1999) (Vardiman et al. 2002) (Vardiman et al. 2009). 
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To do a successful AML diagnosis it is essential an integration of 
clinical,hematological, morphologic, immunophenotypic and genetic features in a 
systematic way (Lowenberg et al. 1999) (M. Smith et al. 2004). 
 
 
TABLE 3 – 2008 WHO classification of AML  (Abdul-hamid et al. 1999) (Vardiman et al. 2002) 
(Vardiman et al. 2009) 
 
Acute myeloid leukemia 
with recurrent genetic 
abnormalities 
 AML with t(8;21)(q22;q22), (AML1/ETO) 
 AML with abnormal bone marrow eosinophils and 
inv(16)(p13q22) or t(16;16)(p13;q22), (CBF/MYH11) 
 Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12), 
(PML/RAR) and variants 
 Acute myeloid leukemia with 11q23 (MLL) abnormalities 
Acute myeloid leukemia 
with multilineage dysplasia 
 Following MDS or MDS/MPD 
  Without antecedent MDS or MDS/MPD, but with dysplasia in 
at least 50% of cells in 2 or more myeloid lineages 
Acute myeloid leukemia 
and myelodysplastic 
syndromes, therapy 
related 
 Alkylating agent/radiation–related type  
 Topoisomerase II inhibitor–related type (some may be 
lymphoid)  
 Others 
 
Acute myeloid leukemia, 
not otherwise categorized 
(NOS) 
 Acute myeloid leukemia minimally differentiated  
 Acute myeloid leukemia without maturation  
 Acute myeloid leukemia with maturation  
 Acute myelomonocytic leukemia 
  Acute monoblastic/acute monocytic leukemia  
 Acute erythroid leukemia  
  Acute megakaryoblastic leukemia 
  Acute basophilic leukemia  
 Acute panmyelosis with myelofibrosis  
 Myeloid sarcoma 
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3. VASCULAR ENDOTHELIAL GROWTH FACTORS AND TUMOR ANGIOGENESIS 
 
Angiogenesis is the growth of new blood vessels from pre-existing ones by 
sprouting of endothelial cells. The angiogenic process is tightly regulated by 
several proangiogenic and antiangiogenic factors, which establish the balance that 
regulates blood vessel formation. In a normal adult the vasculature is remarkably 
quiescent and angiogenesis occurs only in some physiological conditions like the 
female reproductive cycle (ovulation, menstruation, implantation, pregnancy) or 
wound healing. Angiogenesis in adults is therefore largely restricted to 
pathological situations, such as diabetic retinopathy, rheumatoid arthritis, 
psoriasis and tumor growth (Hanahan and Folkman et al. 1996).  
Many factors with angiogenic activity have been identified to date. The first 
to be identified were the fibroblast growth factors (FGF-1 and bFGF), others 
include the transforming growth factors (TGF-α and TGF-β), platelet-derived 
growth factor (PDGF), hepatocyte growth factor (HGF), granulocyte colony-
stimulating factor (G-CSF), tumor necrosis factor-alpha (TGF-α), platelet-derived 
endothelial growth factor (PD-ECGF), interleukin-8 and prostaglandins (PGE1 and 
PGE2). However, the vascular endothelial growth factor (VEGF), actually known as 
VEGF-A, because it acts in most situations that require angiogenesis, is one of the 
most important factors modulating angiogenesis (Ute Modlich and Roy Bicknell).   
VEGF belongs to the Vascular Endothelial Growth Factors (VEGFs) family of 
secreted polypeptides, which are central regulators of vasculogenesis during  
embryonic development and angiogenesis in the adult life. The mammalian VEGF 
family consists of six VEGF ligands which arise as different splice variants and 
processed forms with different biological activities: VEGF-A commonly referred as 
VEGF), VEGF-B, VEGF-C, VEGF-D, the viral homolog VEGF-E and placenta growth 
factor (PLGF). These ligands are described to signal through three tyrosine kinase 
receptors designated as VEGF receptor-1 (also known as FLT1), VEGF receptor-2 
(also known KDR) and VEGFR-3 (also known FLT4) and also through co-receptors 
such as heparan sulphate proteoglycans (HSPGs) and neuropilins (NPs). This 
happens in an overlapping way with different affinities and selectivities (Olsson et 
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al. 2006 ) (Ellis and Hicklin et al. 2008) (Schmidt and Carmeliet et al. 2011). VEGF-A 
binds to VEGFR-1 and VEGFR-2; PLGF and VEGF-B binds to VEGFR-1; VEGF-C and 
VEGF-D bind to VEGFR-3. VEGF-C and –D, depending on the species and due to 
proteolytic processing may bind to VEGFR-2, however with lower affinity than to 
VEGFR-3. This variety of VEGF ligands to different VEGFRs provides distinct binding 
specificities which contribute to their diversity of biological function (Olsson et al. 
2006).  
It is now well recognized that angiogenesis is essential for the growth of solid 
tumors. The angiogenic cascade leading to tumor vascularization can be divided 
into 2 general phases: the pre vascular phase, where a tumor remains in a 
dormant state with a small size, and the vascular phase where tumor is able to 
recruit its own vasculature, which occurs when its size is increased and the levels 
of hypoxia are higher. Only after a tumor acquires its own blood supply can it 
expand in size (Schmidt et al. 2011).   
VEGF mediates numerous changes within the tumor vasculature, including 
endothelial cell proliferation, migration, invasion, survival, chemotaxis of bone 
marrow-derived progenitor cells, vascular permeability and vasodilation (Ellis and 
Hicklin et al. 2008). Overexpression of VEGF is therefore associated with tumor 
progression and poor prognosis in many tumor systems as colorectal carcinoma, 
breast cancer, prostate cancer, lung cancer and melanoma (Hicklin and Ellis et al. 
2005). There are actually several anti angiogenic cancer therapy approaches 
conduced in order to inhibit VEGF signaling (Ellis and Hicklin et al. 2008).  
  
3.1 Angiogenesis in Acute Myeloid Leukemia 
 
Initially angiogenesis was considered to not, or only minimally contribute to 
the pathogenesis of non-solid tumors, like leukemias. Actually it has become 
evident that the microvasculature of the BM plays an important role in 
hematopoiesis both in health and in disease, and a role for angiogenesis in the 
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pathophysiology of hematological malignancies has been suggested, highlighting 
the importance of the BM microenvironment in regulating hematopoiesis.  
Several studies demonstrated an increase of angiogenesis in several 
hematological malignancies, such as multiple myeloma, leukemias and 
myelodysplasic syndromes. For example, an increased microvessel density in the 
bone marrow of patients with AML has been observed, suggesting an important 
role for angiogenesis in disease development and progression (Padró et al. 2013). 
Angiogenesis is stimulated upon infiltration of leukemic blasts in the BM (Schmidt 
et al. 2011) and both leukemic blasts and cells from the BM microenvironment 
secrete angiogenic growth factors and mediators (Ayala et al. 2009). In AML the 
paracrine exchange of growth factors between blasts and endothelial cells is 
believed to contribute to disease pathogenesis while the bone marrow 
angiogenesis is promoted by growth factors released by the leukemic blasts. The 
VEGF family of growth factors has been indicated as one of the most important 
inducer of angiogenesis and several members have been shown to be 
constitutively expressed by AML blasts (Loges et al. 2005).  
 In addition to release of VEGF to stimulate angiogenesis, subsets of leukemic 
cells also express its receptors - VEGFR-1, VEGFR-2, VEGFR-3 (Fragoso et al. 2006) -  
and some studies in human leukemias showed that VEGFRs may be essential for 
tumor cell growth by promoting VEGF/VEGFR autocrine loops (Hicklin et al. 2005) 
such as the VEGF/VEGFR-2 autocrine loop which support leukemic cell survival and 
migration (Dias et al. 2000). 
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FIGURE 2 –VEGF/VEGFRs signaling axis involved in leukemia growth are represented with bold 
arrows. VEGF-A signalized through VEGFR-1 and VEGFR-2 promoting angiogenic and 
vasculogenesis stimulus; VEGF-C signaling through VEGFR-3 are involved in lymphangiogenic 
stimulus, mainly during embryonic development. In addition to their well  established functions in 
angiogenesis and lymphangiogenesis, this signaling axis is suggested to be also related to leukemia 
progression and chemotherapeutic resistance by establishment of autocrine/paracrine angiogenic 
loops. 
 
3.2 VEGF-C/VEGFR-3 signaling axis in AML 
 
Besides VEGF-A, another member of VEGF family – VEGF-C - has been linked 
to the survival and proliferation of leukemic blasts in subsets of acute leukemias, 
due to stimulation of proangiogenic factors production and autocrine/paracrine 
signaling (Dias et al. 2002). 
VEGF-C is characterized mainly as a lymphangiogenic and angiogenic growth 
factor, signaling through VEGFR-3 (FLT-4) with greater, or VEGFR-2 (KDR), with 
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VEGF-C mature form 
Pre-propeptide 
Propeptide 
lower binding affinity, respectively (Dias et al. 2002). Intracellular VEGF-C 
undergoes proteolytic processing leading to a variety of precursor forms; during 
the process VEGF-C acquires the ability to bind and to activate VEGFR-2, and 
increases its affinity and activating properties towards VEGFR-3 (Figure 3). It has 
been proposed that biosynthesis of VEGF-C as a precursor prevents unnecessary 
angiogenic effects raised by VEGFR-2 signaling, and allows VEGF-C to signal 
preferentially via VEGFR-3 (Joukov et al. 1997).  
 
 
 
 
 
FIGURE 3 – Squematic model of the proteolytic processing of VEGF-C. Adapted from (Joukov et al. 
1997). 
61 KDa 
58 KDa 
58 KDa 
31 KDa 
21 KDa 
21 KDa 
31 KDa 
Sequence signal N-terminus VEGF homology domain C-terminus 
dissulfite bonds covalent bonds 
INTRODUCTION 
 
14 
 
VEGF-C expression has been linked to many tumor events, namely 
intratumoral lymphangiogenesis and metastasis, being reported as an important 
factor in tumor development and progression, particularly by signaling through 
VEGFR-3. The VEGF-C/VEGFR-3 signaling axis also exerts direct effects on cancer 
cells leading to tumor progression (Su et al. 2007).  
In AML, VEGF-C has been indicated as a relevant modulator of leukemic cell 
proliferation, migration and also chemotherapeutic resistance through a VEGF-
C/VEGFR-3 paracrine loop. Leukemic blast cells release proangiogenic growth 
factors in the bone marrow which stimulate the BM endothelium, resulting in 
production of VEGF-C by endothelial cells. VEGF-C in turn signals through VEGFR-3 
expressed in leukemic blasts, creating a paracrine angiogenic loop which promotes 
leukemia survival and proliferation. However, it is also hypothesized the existence 
of an autocrine loop since certain subsets of leukemias release VEGF-C.  
Finally, studies in pediatric AML reported that mRNA levels of VEGF-C in 
primary pediatric leukemic cells are closely related to increased in vitro drug 
resistance, and a longer time to kill most blast cells in vivo upon drug exposure, 
revealing an influence of endogenous VEGF-C in leukemic cell survival. Whether 
this VEGF-C acts in an autocrine or paracrine loop is not known (De Jonge et al. 
2008).   
 
3.3 VEGF-C and AML cell resistance to apoptosis: Bcl-2 family 
 
Bcl-2 family proteins are key regulators of the mitochondrial or intrinsic 
apoptotic pathway, inducing or preventing the release of apoptogenic proteins to 
determine the fate of the cell after receiving a physical or chemical insult. All 
members of this family are involved in the regulation of cell death, with some of 
them being anti-apoptotic, like Bcl-2 itself, and other being proapoptotic. The 
antiapoptotic protein Bcl-2 is overexpressed in many tumor cells promoting 
tumorigenesis and chemotherapy resistance by inhibition of apoptosis  (Marzo et 
al. 2008).  
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Several studies link VEGF family and Bcl-2 expression in AML, pointing this 
factor as one of the main effectors of VEGF-induced survival of leukemic cells. 
Both VEGF-A and VEGF-C have been shown to induces Bcl-2 expression on primary 
leukemias and cell lines (Dias et al. 2002).  
 
 4.  CHOLESTEROL AND ACUTE MYELOID LEUKEMIA (AML) 
 
4.1 Cellular cholesterol: physiological significance and homeostasis 
 
Cellular cholesterol is an important membrane component in higher 
eukaryotes due to its role in the generation of a semipermeable barrier between 
cellular compartments and in the regulation of membrane fluidity. Cholesterol is 
enriched in the plasma membrane, where it normally accounts for 20-25% of the 
lipid molecules. Cholesterol is also a relevant factor in the modulation of the 
functions of membrane proteins, participating in several membrane trafficking and 
transmembrane signaling processes. All nucleated cells can synthesize cholesterol 
from acetyl CoA through the mevalonate pathway; this is called the de novo 
cholesterol synthesis, one of the two sources of cellular cholesterol. Another 
source is the dietary intake of cholesterol obtained with food (Ikonen et al. 2008), 
the dietary cholesterol is uptaken by the cells through Low Density Lipoprotein 
LDL, which is the major cholesterol carrier molecule in the plasma (Goldstein and 
Brown et al. 1974).  
Cholesterol homeostasis is achived by coordinated transcriptional control of 
cholesterol-regulating genes (Banker et al. 2004). The synthesis of cellular 
cholesterol, uptake and processing reactions are mainly regulated by two nuclear 
receptors systems: sterol regulatory element binding proteins (SREBPs), activated 
in the presence of poor cellular cholesterol conditions, and liver X receptors 
(LXRs), activated when there is an excess of cellular cholesterol (Ikonen et al. 
2008).  
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SREBP is located in the endoplasmatic reticulum (ER) and in conditions of low 
cellular cholesterol levels is carried to the Golgi complex (GC) where undergoes 
proteolytic processing, the resulting fragment is transported to the nucleus 
activating transcription of genes such as HMG-CoA and LDLR, responsible for de 
novo cholesterol biosynthesis and uptake of cholesterol by the cell, respectively 
(Ikonen et al. 2008).  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 – Squematic representation of cholesterol efflux/influx. LDL transports dietary 
cholesterol in the plasma and it is uptake by cells through LDLR, whereas HDL includes excess 
cholesterol excreted by cells and delivers to steroidogenic cells in the kidneys and hepatocytes in 
the liver, through SRB1 receptor, for steroid hormone synthesis and biliary excretion, respectively.  
 
LXRs are activated with excess of cholesterol but the crosstalk between their 
activation and membrane cholesterol levels is not well understood. However, it is 
established that higher cholesterol levels promote an increase in ABC transporters 
in plasma membrane, such as ABCA1, which allows cholesterol efflux from the 
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cells. ABCA1 is a key modulator of cellular cholesterol export, acting as a mediator 
in HDL particle formation and maintenance of its plasma levels. The binding of 
APOA-I to the ABCA1 transporter triggers a multi-step process by which lipids as 
cholesterol are transferred to the APOA-I to generate HDL precursors. Then, HDL 
enters the circulation and in the liver (hepatocytes) and in the kidney 
(steroidogenic cells) scavenger receptor B1 (SRB1) are responsible for the uptake 
of cholesterol contained in HDL particles, for conversion to bile acids and for 
steroid hormone synthesis, respectively (Hoang et al. 2013) (Ikonen et al 2008). 
 
4.2 Cholesterol, lipid rafts and cancer 
 
Tumor cells metabolism has shown to be altered in many cancers and it has 
begun to emerge a link between cholesterol levels and disease progression, 
aggressiveness and prognostic. Cholesterol is considered to have survival effects 
on cells and this may be related with the accumulation of cholesterol in lipid rafts 
domains at the plasma membrane (Scheinman et. al 2013). Lipid rafts consist of 
dynamic assemblies of cholesterol and sphingolipids known as lipid micro-
environments on the cell surface that contain a set of proteins. Lipid rafts can 
change their size and composition in response to intra or extracellular stimulus 
favoring specific protein-protein complexes interaction and resulting in the 
activation of signaling cascades (Simons et al. 2000).  
Lipid rafts are composed by subsets of caveolae, cell surface invaginations 
formed from lipid rafts by polymerization of caveolins – hairpin-like 
palmiotoylated integral membrane proteins that tightly bind cholesterol. Lipid 
rafts have been implicated in various physiological cellular processes (Murai et al. 
2012) but signal transduction may be the most important role of lipid rafts at cell 
surface (Simons and Toomre et al. 2000). Many proteins, such as receptor tyrosine 
kinase family members (RTK), involved in signal transduction precisely exhibit their 
functions through lipid rafts (Patra et al. 2008). Changes in the molecular structure 
of lipid rafts domains may cause aberrant signaling (Patra et al. 2008) and because 
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of that, lipid rafts have been implicated in signaling pathways and in cancer 
progression (Murai et al. 2012).     
 
4.3 Cholesterol in AML 
 
In AML cells, cholesterol metabolism is deregulated (Li et al. 2003). Leukemic 
cells from patients have a higher uptake of LDL as compared to mononuclear blood 
cells and an increased HMG-CoA reductase (HMG-CoAR) activity (Banker et al. 
2004). Compared with normal cells, cultured AML cells overexpress the genes for 
LDLR and HMG-CoAR (Vitols et al. 1994). Tumor cells are characterized by rapid 
proliferation, and presumably one of the advantages of being cholesterol enriched 
is the requirement of cholesterol for new membrane synthesis (Li et al. 2003). 
Cholesterol levels are also reported to increase in AML cells that are treated in 
vitro with sub lethal doses of radiation or chemotherapeutics but when cholesterol 
biosynthesis is inhibited with a HMG-CoAR inhibitor (mevastatin) or upon LDL 
deprivation by serum starvation, AML cells become sensitize to radiation and 
chemotherapeutic drugs (Banker et al. 2004). This suggests a protective role for 
cellular cholesterol and exogenous LDL against the cytotoxic effects 
chemotherapy.   
 
4.4 Cholesterol influence in VEGF/VEGFRs signaling: AML 
 
Lipid rafts work as complex signaling centers in cellular membranes and its 
function has been related to VEGF signaling, namely with VEGF signaling through 
VEGFR-2 in endothelial cells (Labrecque et al. 2003) and VEGFR-1 in leukemic cells 
(Casalou et al. 2011) suggesting a role for this cholesterol-rich membrane domains 
on VEGF signaling.  
VEGFR-2 is reported to be located at caveolae sub-domains of lipid rafts, 
associated with the caveolin-1 protein in endothelial cells (Labrecque et al. 2003) 
as well as VEGFR-1 in subsets of AML cells (Casalou et al. 2011). VEGFR-1 location 
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in caveolae is promoted by stimulation of VEGF/PLGF ligand, and it was also seen 
that membrane cholesterol levels influence this location and receptor functions. 
Cholesterol extraction from AML cell lines with Methyl-β-Cyclodextrin abolishes 
VEGFR-1 activation induced by PLGF and in contrast, cholesterol enrichment with 
cholesterol included in Methyl-β-Cyclodextrin increases receptor expression and 
activation in presence or absence of the PLGF ligand. Increased VEGFR-1 activation 
in higher cellular cholesterol conditions may contribute to AML expansion and 
development, once signaling through VEGFR-1 is related to augmented cell 
viability, migration and VEGF production, emphasizing a link between cholesterol 
avidity and acute leukemias (Casalou et al. 2011). 
 
 
 
 
 
 
 
 
 
 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS 
AIMS 
21 
 
Some subsets of AML express ligands and receptors of the VEGF family and VEGF 
signaling has been shown to promote leukemic cell proliferation and survival leading to 
AML progression and aggressiveness. Among VEGF members, VEGF-C is particularly 
important, as it´s expression has been linked to the resistance to chemotherapy by 
AML cells.  As resistance to chemotherapy in one of the main problems AML patients 
have to deal with, identifying factors that promote VEGF-C production and signaling 
could help in the search for better treatments for this disease.  
Cholesterol has also pro-proliferation and pro-survival effects on AML cells. 
Additionally it is involved in the modulation of VEGFR-1 at the cellular membrane, 
influencing its activity. For this reason we hypothesized that cholesterol may affect 
VEGF-C expression and signaling. 
 
To answer that we had three main goals: 
1) To enrich and partially deplete intracellular cholesterol levels in AML 
cells  
2) To analyze whether intracellular cholesterol content affects VEGFC and 
VEGFR-3 expression 
3) To analyze whether intracellular cholesterol content affects Bcl-2 
expression  as Bcl-2 is a VEGFC signaling effector that promotes AML cell 
survival 
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CELL CULTURE 
HEL and THP1 cell lines were used as models for human erythroleukemia and 
human monocytic leukemia, respectively, both subsets of AML. Cells were cultured in 
RPMI 1640 medium supplemented with 10% FBS, 1% L-Glutamine and 1% 
streptomycin/penicillin. HUVEC cells were used to perform qPCR experiments, and 
were cultured in EBM2 containing 5% FBS in a flask coated with gelatin 0.2%. 
 
CELL VIABILITY 
Cell viability was assessed through Trypan blue exclusion method. 10 μl of cells 
were mixed with 2μl of Trypan Blue in triplicate. Cells stained with blue (death cells) 
were then counted.  
 
MβCD AND MβCD + CHOLESTEROL COMPLEXES SOLUTIONS 
MβCD and MβCD + cholesterol complexes solution were done with base on 
(Klein et. al 1995) and used, respectively, to remove and to enrich cells with 
cholesterol. For MβCD solution, MβCD (Sigma-Aldrich) was dissolved into 1x PBS with 
constant stirring at 80ºC and when solution has reached this temperature a stock 
solution of isopropanol/chloroform (2:1) was added. For MβCD + cholesterol 
complexes the same procedure was follow but cholesterol was previously dissolved 
into isopropanol/chloroform (2:1) solution and then added to the MβCD dissolved into 
PBS at 80ºC. As a control solution for the experiment execution 
isopropanol/chloroform (2:1) was dissolved into 1x PBS. All these three solutions were 
stored and managed at room temperature.  
 
ENRICHMENT AND DEPLETION OF CELLULAR CHOLESTEROL CONTENT FROM CELLS 
HEL and THP-1 cell lines at 0.6x106 cell/mL concentration were plated in serum-
free RPMI 1640 medium for about 12 hours and then treated with MβCD (from 0.2 
mM to 10 mM), MβCD + cholesterol complexes (0.2 mM MβCD + 0.02 mM cholesterol) 
and isopropanol/chloroform (2:1) for time periods of 4 to 24 hours, according with the 
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different experiments, at 37ºC. Cells were then collected into eppendorfs and 
centrifuge at 1200 RPM for 5 minutes. Supernatants were removed and cellular pellets 
stored at -20 ºC or -80 ºC depending on the future analyzes. 
 
QUANTIFICATION OF CELLULAR CHOLESTEROL CONTENT 
Cellular cholesterol content was measured by Amplex® Red cholesterol Kit 
(Invitrogen), a fluorometric method for the sensitive quantification of cholesterol. 
First, several dilutions of cholesterol reference standard (2 mg/mL) were prepared in 
order to obtain a standard curve: 0μg/mL, 1μg/mL, 2μg/mL, 4μg/mL and 8μg/mL. 
Cholesterol reference standard was diluted into 1x Reaction Buffer (0.5M potassium 
phosphate, pH 7.4, 0.25M NaCl, 25mM cholic acid, 0.5% Triton® X-100) as well as 
cellular pellets to proceed with cell lysis. 50 μl of each cholesterol standard dilution 
and cellular sample were plated into a 96 wells plate and then 50μl of 300 μM 
Amplex® Red Reagent (2 U/mL horseradish peroxidase, 2U/mL cholesterol oxidase and 
0.2U/mL cholesterol esterase) was added to each plate micro well for the reaction 
beginning. Plate was incubated for 30 minutes at 37ºC, protected from light, and then 
absorbance was measured at 573 nm (Infinite® M200, Tecan). 
 
PROTEIN QUANTIFICATION 
Protein concentrations were determined using the Bio-Rad Laboratories DC 
protein assay kit, a colorimetric assay for protein concentration after detergent 
solubilization. Using BSA (100 mg/mL) as a protein reference several dilutions were 
done in order to obtain a standard curve: 0.2 mg/mL, 0.4 mg/mL, 0.8 mg/mL and 1.6 
mg/mL. BSA reference and cellular pellets were diluted into Reaction Buffer 1x or into 
RIPA buffer composed by 50mM Tris, pH 7.4, 150mM NaCl, 5mM EDTA, 1% NP-40, 
0.1% SDS, 0.5% Sodium deoxycholate, 1 pellet protease inhibitors (Roche), 1M NaF and 
100mM Na3VO4 to proceed with cell lysis. 5 μl of each cellular sample and BSA 
standard dilution was plate into a 96 wells micro plate and then 25μl of Reagent A’, 
composed by Reagent A (Sodium hydroxide) and Reagent S (Sodium dodecyl sulfate), 
was added to each micro well followed by 200μl of Reagent B (Folin reagent). Plate 
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was incubated for 5 minutes at room temperature and then absorbance was measure 
at 750 nm (Infinite® M200, Tecan). 
 
RNA EXTRACTION  
RNA was extracted using TRIzol® reagent method which maintains the integrity 
of RNA during cellular components disruption. 500 μl of TRI® reagent (Sigma-Aldrich) 
was added to each cellular pellet for sample homogenization, then chloroform 
(200μl/mL TRIzol®) was added and samples centrifuged at 14000 RPM for 20 minutes 
at 4ºC.The top aqueous phase of each tube, containing the RNA was transferred to 
new tubes and mixed with isopropanol (0.5μl/μl TRIzol®) and kept O/N at -20 ºC. Tubes 
were then centrifuged at 14000 RPM for 20 minutes at 4ºC to precipitate RNA, 
supernatants were removed and the pellets were washed in ethanol 80% (in DEPC-
treated water). Pellets were resuspendend into DEPC-treated water and quantification 
was performed on NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). The 
majority of these steps were performed on ice to prevent RNA degradation. 
 
CDNA SYNTHESIS    
The cDNA synthesis for quantification of transcripts was performed from 500 ng 
of total RNA using Random Primers (Invitrogen™), 10 mM dNTPs and DEPC-treated 
water up to 12 μl. This mix was incubated 5 minutes at 65 ºC and then a mix containing 
5x First Strand Buffer (Invitrogen™), 0.1M DTT (Invitrogen™) and RNAse Out 
(Invitrogen™) was added and. Tubes were incubated at 25 ºC for 2 minutes and then 
1μl of SuperScript enzyme (Invitrogen™) was added and incubated at 25 ºC for 15 
minutes, followed by 50 ºC during 50 minutes and 70ºC for 15 minutes. In the end of 
these reactions cDNA was diluted into H2O redistilled (1:3).  
 
QUANTITATIVE PCR (qPCR) FOR mRNA QUANTIFICATION 
Levels of mRNA were measured by qPCR through ViiA™ 7 Real time PCR system 
(Applied Biosystems) in 392-well plates, using SYBR-Green. This method allows the 
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amplification and quantification of a target gene, obtained through emission of a 
fluorescent dye that intercalates into de DNA strands. Relative expression was 
calculated using the comparative method 2-ΔCt and sample normalization was 
performed with 18S mRNA expression. For the amplification reaction a 8.3 μl mix 
containing SYBR® Green (Applied Biosystems), 10 μM of both forward (FWD) and 
reverse (REV) primers, H2O redistilled and 1 μl of cDNA was prepare per well plate. The 
sequences of the primers used in this study are listed in TableS1 on Supplementary 
information section. 
 
PROTEIN EXTRACTION AND WESTERN-BLOTTING 
Analysis of protein content in cells subjected to MβCD treatments was 
performed by western-blotting.  
Cellular pellets were ressuspendend into RIPA buffer, maintained on ice for 30 
minutes to perform cell lysis and then centrifuged at 13400 RPM for 20 minutes at 4 
ºC. Supernatants (containing protein) were stored into new tubes and protein levels 
were measured.  
Proteins were separated by sodium-docedyl sulfate-polyacrilamide gel 
electrophoresis (SDS-PAGE), this method allows the sorting of proteins by their 
molecular weight and charge. SDS-PAGE gel composition and porosity is chosen based 
on the specific weight of the target proteins to be analyzed. Here, a 15% gel was used 
since we wanted to separate proteins of 21-61 KDa size. This gel is composed of two 
acrylamide mixes: the resolving or separating gel (Table S6), and, on gel top, a stacking 
gel (Table S7) composed with pores that compresses proteins in a thin starting zone.  
Before sample loading into the gel proteins were denatured through the addition of 
Laemli Buffer with 10% β-mercaptoethanol to an equal protein volume (equivalent to 
11μg) and heat for 10 minutes at 95 ºC. β-mercaptoethanol denatures protein via its 
ability to clive disulfide bonds, and therefore disrupts both the tertiary and the 
quaternary structure of proteins. Then, samples, and 7μl of protein ladder (Precision 
Plus Protein™, Bio-Rad) with molecular weights standard, were loaded in the gel, and 
run at 140V for about 2 hours in an electrophoresis equipment (Mini Trans-Blot® 
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Electrophoretic Transfer Cell, Bio-Rad) filled with Running Buffer pH 8.3 (25 mM Tris, 
190 mM Glycine and 0.1% SDS). Proteins are denatured in the presence of a detergent, 
SDS in this case, being coated with a negative charge and, therefore, they will run to 
the positive pole when electric current is applied to the gel.  
Next steps comprises the transfer of the proteins contained in the gel to a 
nitrocellulose membrane, by electric current, and the exposition of proteins on thin 
surface of the membrane for detection. This transfer was also performed with the Mini 
Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad) filled with Transfer Buffer (250 mM 
Tris, 1250 mM Glycine, 10% methanol), O/N, 4ºC, at 40V. After transfer, membrane 
was washed three times, during 10 minutes, with TBST and a blocking step was done 
to prevent the non-specific interaction of the antibody. Membrane was incubated with 
5% milk in TBST (Table S12) for 1 hour at room temperature with shaking (VWR® 
Microplate shaker). Then the membrane was incubated with primary antibody rabbit 
anti-human VEGF-C (1:1000; Invitrogen™) diluted into TBST O/N, at 4ºC, shaking. After 
washing membrane three times with TBST, the membrane was then incubated with 
the secondary antibody anti-rabbit IgG conjugated with horseradish proxidase (HRP) 
enzyme (1:5000; W4018, Promega) for 2 hours at room temperature with shaking, and 
finally again washed three times with TBST. 
At the end, the bands corresponded to the specific protein (VEGF-C) were 
detected by incubating the membrane with the substrate for HRP enzyme (Pierce ECL 
Western blotting substrate, Thermo Scientific) and osbserved in a Bio-Rad molecular 
image system (Chemidoc XRS+) with Image Lab software. The bands obtained were 
quantified through optical density with ImageJ software.  
The procediment described above was also performed to detect β-actin, the 
internal protein control used in these work with the primary antibody goat anti-human 
β-actin (1:5000; Santa Cruz Biotechnology) and the secondary antibody donkey anti-
goat IgG conjugated with  HRP enzyme (1:5000; sc-2020; Santa Cruz Biotechnology). 
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FLOW CYTOMETRY 
Flow cytometry was used to analyze the pattern of VEGFR-3 expression at cell 
surface. After exposure to treatments with MβCD, MβCD + cholesterol complexes and 
isopropanol/chloroform (2:1) cells at 0.5x106 were collected, centrifuged for 5 
minutes, 1200 RPM at room temperature and then washed twice with 1x PBS. Cells 
were then fixed through the addition of 300µl 4% PFA (paraformaldehyde) followed by 
15 minutes incubation at room temperature. After wash twice with 1x PBS samples 
were incubated with the primary antibody rabbit anti-VEGFR-3 (1:100; ab27278; 
Abcam) diluted into PBS/0.5% BSA and blank samples were incubated with PBS/0.5% 
BSA (Table S13), for around 60 minutes at 4ºC. Next samples were incubated with the 
secondary antibody 488 donkey anti-rabbit (1:400; A21206; Alexa Fluor®), after 
washing twice with 1xPBS, for 60 minutes at 4ºC. Finally, samples were washed as 
described previously, ressupend into 1x PBS and then the results accquired with BD 
FACSCalibur™ flow cytometer (BD Biosciences). The final data was analyzed with 
FlowJo software.  
 
STATISTIC ANALYSIS  
Statistical analysis was performed with GraphPad® Prism 5.0 software. The 
statistical significance was determined using student’s T-test (p > 0.05) and error bars 
represent the standard error of the mean.  
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Depletion of cellular cholesterol with MβCD in THP-1 and HEL cell lines 
 
One of the aims of this study was to understand if cholesterol depletion 
affected the expression of factors related to leukemia cell survival. Methyl-β-
cyclodextrin (MβCD) has been largely used in recent years to manipulate the 
cholesterol composition of cellular membranes, being capable of partially deplete 
cholesterol from cells. For this, as a first approach, we treated HEL and THP-1 cells with 
0,2 mM MβCD for 4 hours and evaluated intracellular cholesterol content using 
Amplex© Red Cholterol Kit (Invitrogen). As it can be seen in Figure 1A, in these 
conditions, a decrease in intracellular cholesterol content is observed in both cell lines, 
however with a small sample size (n=3) this is not statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 – Lower concentration of MβCD deplets cholesterol from cells.   
(A), (B) Cholesterol depletion in HEL and THP-1 cell line, respectively. Cholesterol levels were measured 
using Amplex© Red Cholesterol Kit in relation to protein levels. n=3 
A  
B  
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Increasing MβCD concentrations were then used in order to decrease 
intracellular cholesterol content. In figure 2 we can observe that using MβCD 
concentration from 1mM to 10 mM results in a more efficient cholesterol depletion 
than with 0.2 mM in HEL cell line (Figure 2A). In THP-1 cell line (Figure 2B) there is a 
trend to decrease of cholesterol levels with 1mM, but it is not statistically significant. 
However 2mM MβCD depletes cholesterol significantly from THP-1 cells.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
FIGURE 2 – 2mM of MβCD partially depletes cholesterol in both cell lines. (A), (B) Cholesterol depletion 
in HEL and THP-1 cell line, respectively. Cholesterol levels were measured using Amplex© Red 
Cholesterol Kit (Invitrogen) in relation to protein levels. n=3 
* 
A  
B  
* 
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* 
* 
p=0,026 
p=0,002 
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With the intent of experimenting even higher concentrations of MβCD, to maximize 
cholesterol removal, 5mM and 10 mM concentrations were tested also in both cell 
lines. It was verified that 5mM of MβCD reduces cholesterol levels by half in relation to 
control and that 10 mM of MβCD reduces even more, however there is no significant 
difference in depleted cholesterol levels between these two conditions but a further 
decrease in 10 mM is seen, but this is not statistically significant in relation to 5mM. 
Both concentrations decrease cholesterol in relation to control samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 – Depletion of cellular cholesterol with MβCD is concentration dependent.  
(A), (B) Cholesterol depletion in HEL and THP-1 cell line, respectively. Cholesterol levels were measured 
using Amplex© Red Cholesterol Kit in relation to protein levels.  n=3 
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B  
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These results confirm that MβCD depletes cholesterol from cells efficiency in a 
concentration-dependent manner.  
 
 Enrichment of cellular membrane with cholesterol through MβCD + cholesterol 
complexes in THP-1 and HEL cell lines 
 
MβCD is also recognized as a vehicle for hydrophobic molecules, forming 
inclusion complexes with several compounds (Del Valle et al. 2004) and has higher 
affinity for encapsulating sterols, in particular cholesterol (Kilsdonk et al. 1995). Since, 
as in addition to deplete cholesterol in cells we also aimed at increasing intracellular 
cholesterol content, we used MβCD has a vehicle to delivery cholesterol to cellular 
membranes in HEL and THP-1 cell lines. By using 0.2 mM of MβCD + cholesterol 
complexes (0.02 mM of cholesterol) we were able to increase cholesterol content by 
around two fold in both cell lines. (Figure 4A and B).  
 
 
 
 
 
 
 
 
 
FIGURE 4 – Low concentrations of MβCD are capable of transport and enrich cellular membrane with 
cholesterol.  (A), (B) Cholesterol enrichment in HEL and THP-1 cell line, respectively, after 4 hours 
treatment. n=3 
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 MβCD reduces cell viability  
 
As a molecule or molecular carrier that interferes with the normal lipid 
equilibrium of cellular membranes by depleting or adding cholesterol, it is important to 
analyze the effects that MβCD and MBCD+cholesterol complexes have in cell viability.   
For this, cells were exposed to the different concentrations of MβCD previously 
tested for different periods of time (4, 10 and 24 hours) and it was observed that cell 
viability is reduced with increasing concentration of MβCD and long times of exposure 
(Figure 5). From 1mM to 10 mM a proportional decrease in percentage of viable cells is 
observed throughout time, except for the 0,2mM MβCD condition. This viability 
reduction is demonstrated in both HEL (Figure 5A) and THP-1 cells (Figure 5B).  
 
 
 
                                                                          
 
 
 
 
 
 
  
 
 
  
  
FIGURE 5 - Higher concentrations of MβCD and longtime exposures reduces cell viability. (A) HEL cell 
line and (B) THP-1 cell line percentage of viable cells with different MβCD concentrations. Cell viability 
was assessed by Tripan Blue Exclusion. n=3 
B 
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  0.2 mM MβCD + cholesterol complexes minimally affect cell viability 
 
Next we analyzed cell viability with 0.2 mM MβCD + cholesterol complexes and 
observed around 80% of viable cells in both HEL and THP-1 cell line after 4, 10 and 24 
hours of exposure. Noticeably, there is also a small decrease in cell viability after 10 
and 24 hours in both cell lines and also in the control.          
 
                            A 
                         
 
                      
                       
 
 
 
                            B 
 
 
 
 
 
 
 
 
FIGURE 6 – Complexes of 0.2mM MβCD and cholesterol do not interfere with cell viability . (A) HEL cell 
line and (B) THP-1 cell line percentage of viable cells after treatment with 0.2 mM MβCD + 0.02mM 
Cholesterol complex during different exposure periods. Cell viability was assessed by Tripan Blue 
Exclusion. n=3 
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Amplification Plot 
 The ribosomal subunit 18 S is an adequate housekeeping gene to use as internal 
control to quantify mRNA by quantitative PCR in AML cell lines that have been 
exposed to MβCD and MBCD+ cholesterol complexes 
 
To access reliable and accurate gene expression data by quantitative PCR (qPCR) 
it is essential to do the gene expression normalization against internal control genes 
taken as references, this are usually housekeeping genes. Good internal controls are 
genes which expression does not undergo variations due to different cell treatments, 
cellular environment conditions, drugs or biological factors. Since the treatment of 
cells with MβCD was the basis of our experiments we wanted to check among 3 initial 
selected housekeeping genes, which would remain more stable upon treatment. The 
genes selected were 18S, BMG1 and HPTR, as they are regularly used in the lab for 
AML cells. Gene expression was analyzed comparing control and HEL cells treated with 
0.2 mM MβCD and 0.2 mM MβCD + Cholesterol, and it was observed that 18S has the 
more stable amplification curve and furthermore, it amplified during the first few 
cycles of the qPCR reaction.  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 – 18S has the more stable amplification curve in relation to the other genes analyzed in HEL 
cell line. Amplification plot image was get and adapted from ViiA
TM 
7 Real-Time PCR software. 18S 
corresponds to red curve, BMG1 to blue curve and HPTR to green curve. Each curve line from each 
amplification curve corresponds to one sample, showing more stable amplification curves with 18S. 
18S 
BMG1 
HPTR 
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Cholesterol depletion and enrichment modulate the expression of several 
cholesterol homeostasis-related genes 
 
Several genes regulate intracellular cholesterol homeostasis. To assess if cells are 
sensing cholesterol changes, we analysed by qPCR the expression of several 
cholesterol related genes including cholesterol receptors and transporters. 
HEL and THP-1 cell lines were subjected to treatments with MβCD and MβCD + 
cholesterol complexes and, as a first approach, the 0.2 mM concentration was used to 
deplete and to enrich cholesterol, respectively. As it can be seen in figure 8, in relation 
to control, LDLR mRNA expression increases when MβCD is added to cells and 
decreases in MβCD + cholesterol conditions. This is true for both cell lines used. In 
another hand modified LDL receptors such as CD36 and SRB1 mRNA expression show 
no differences between the different conditions for the HEL cell line, while in THP-1 
cells CD36 is increased in both conditions. Finally, ABCA1 mRNA expression is 
significantly decreased in cells treated with MβCD and significantly increased in cells 
treated with MβCD + cholesterol, in both cell lines. 
A 
p=0.0088 
p=0.0017 
p=0.035 
p=0.02 
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FIGURE 8 – Cells are sensible to changes in membrane cellular cholesterol. qPCR for several cholesterol 
modulator genes in HEL cell line (A) and THP-1 cell line (B) genes after 4 hours treatment with 0.2 mM 
MβCD and 0.2 mM MβCD + 0.02 mM cholesterol complexes. mRNA expression is relative to mRNA 
expression of control samples. n=3 
 
These observations suggest that cells are sensible to the alterations caused by 
0.2 mM MβCD, this concentration depletes low levels of cholesterol from cells but it is 
enough to induce alterations in cholesterol homeostasis-related genes at the mRNA 
level. In addition, we confirm that a four-hour treatment with the same concentration 
of MβCD + cholesterol complexes is able to increase the cholesterol content of cells as 
alterations at the level of mRNA of receptors associated with cholesterol uptake and 
efflux are altered.  
 
Bcl-2 mRNA expression is not associated with intracellular cholesterol levels 
 
The Bcl-2 family of proteins has been related to AML, mainly by acting as an anti-
apoptotic factor leading to cell survival and resistance to chemotherapy. We 
hypothesized that the molecular mechanisms involved in Bcl-2 expression in AML 
could be modulated by cellular cholesterol levels and therefore analyzed the 
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expression of Bcl-2 mRNA by qPCR. As it can be seen in figure 9A, Bcl-2 mRNA 
expression in both HEL and THP-1 cells is not change when cholesterol is either 
depleted or enriched.  
 
 
 
 
 
  
 
 
 
FIGURE 9 – Bcl-2 expression is not regulated by cellular cholesterol levels but it seems to increase in 
THP-1 cells treated with MβCD. qPCR for (A) HEL and (B) THP-1 cell lines to determine Bcl-2 mRNA 
expression after 4 hours treatment with 0.2 mM MβCD and 0.2 mM MβCD + cholesterol complexes. 
mRNA expression is relative to mRNA expression of control samples. n=3 
 
 
 VEGF-C mRNA expression increases in cells treated with 0.2 mM of MβCD 
 
VEGF-C, acting through the VEGFR-3, is involved in signaling pathways that lead 
to cell proliferation and AML progression. Here we investigated at mRNA level if its 
endogenous expression is related with membrane cholesterol levels, analyzing VEGF-C 
expression in lower and higher cholesterol conditions by qPCR in both HEL and THP-1 
cell lines. Interestingly, it was observed that VEGF-C mRNA expression is increased in 
relation to control when HEL cells are treated with 0.2 mM MβCD (Figure 10).  In 
another hand no significant differences are observed when cells are treated with 
MβCD + cholesterol complexes. In THP-1 (Figure 10B) VEGF-C expression is increased in 
both high and low cholesterol conditions when compared to control.  
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FIGURE 10 – VEGF-C is increased in low cellular cholesterol levels and VEGFR-3 is decreased in both low 
and high cellular cholesterol levels. qPCR for HEL cell line (A) and THP-1 cell line (B) to determine mRNA 
expression of VEGF-C and VEGFR-3 after 4 hours treatment with 0.2 mM MβCD and 0.2 mM MβCD + 
0.02 mM cholesterol complexes. mRNA expression is relative to mRNA expression of control samples. 
n=3 
 
 VEGFR-3 mRNA expression decreases in both conditions of depletion and 
enrichment of cellular cholesterol with MβCD 
 
In addition to VEGF-C, the expression of VEGFR-3 mRNA was also analysed. In the 
two cell lines we could see that the expression of the receptor decreases in both poor 
and rich cholesterol conditions in HEL cells (Figure 10A). In the THP-1 cell line VEGFR-3 
B 
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mRNA expression is decreased in high cholesterol levels and this is statistically 
significant whereas the decrease observed with low cholesterol levels it is not (Figure 
10B). Taken together these data suggest that VEGF-C expression at the mRNA level 
increases when cells have low concentrations of cholesterol while it is not clear so far 
whether the changes at the VEGFR-3 mRNA levels are related to the alterations at 
cholesterol content levels of cells, or to a non-cholesterol-associated effect of MβCD.  
 
 VEGF-C protein levels increase with lower intracellular cholesterol in one of the two 
AML cell lines studied  
 
To see whether the alterations we observe at the mRNA level are also observed 
at the protein level we investigated VEGF-C protein expression by Western Blot. The 
antibody used to detect VEGF-C is human specific and it may detect 3 different 
proteolytic processed variants but in our hands only two of them were detected 
consistently.  
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FIGURE 11 – VEGF-C protein levels tend to decrease when treated with 0.2 mM MβCD and 0.2 mM 
MβCD + cholesterol complexes in HEL cells. (A) Western-Blotting for VEGF-C detection in HEL cells. (B) 
Optical density for 21 KDa VEGF-C variant form (mature form) and for (C) 31 KDa VEGF-C variant form. 
n=1 
 
In figure 11 and 12, the bands represented correspond to different VEGF-C 
processed forms originated during proteolytic process, the 21 KDa band may 
correspond to the mature form of VEGF-C that is secreted by cells and the 31 KDa band 
may correspond to the processing form just prior to the fully mature.  
In the HEL cell line (Figure 10A) VEGF-C variants show a tendency to decrease in 
both lower and higher cholesterol conditions. In the THP-1 cell line (Figure 12) the 
VEGF-C mature form show a tendency to increase with lower cellular cholesterol levels 
and tend to decrease in higher cholesterol conditions, however this observed trend 
has no statistic significance. 31KDa VEGF-C variant is decreased in higher cholesterol 
conditions, with statistical significance in THP-1 cells.  
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FIGURE 12 – VEGF-C protein levels increase upon cholesterol depletion and decrease with cholesterol 
enrichment in THP-1 cells. (A) Western-blotting for VEGF-C detection in THP-1 cells. (B) Optical density 
for 31 KDa VEGF-C variant (mature form) and for (C) 21 KDa VEGF-C variant. n=3  
 
 
VEGFR-3 levels at the cellular membrane are not affected by changes in intracellular 
cholesterol  
 
  VEGFR-3 is a receptor located at the cellular membrane, to look at the 
expression of VEGFR-3 at the plasma membrane, we used a specific antibody against 
VEGFR-3 and flow cytometry analysis. We did this for the THP-1 cell line. 
We were able to observe that the entire population of THP-1 cells expresses VEGFR-3 
and that both in high and low cholesterol conditions cells express equivalent amount 
of the receptor at the membranes (Figure 13A). As shown by the plots in Figure 13B, 
looking at mean intensity fluorescence values in relation to control it is clear that 
VEGFR-3 remains the same expression level despite the alterations of cholesterol 
content.  
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FIGURE 13 – VEGFR-3 expression in cellular membrane does not undergo significant alterations with 
different cholesterol levels. (A) Representative histograms with percentage of positive cells, for control 
samples (A1) and each cholesterol condition (A2-3) (B) Geometric mean values from flow cytometry 
correspondent to mean intensity of fluorescence in each condition. n=3  
          
The expression of VEGF-C and VEGR-3 is much lower in AML than in endothelial cells 
 
With the intent of understanding how much VEGF-C and VEGFR-3 are expressed 
in AML cells we analyzed the expression of this factors in THP-1 cell line and compared 
it with levels of expression in primary endothelial cells, namely in Human Umbilical 
Endothelial Cells (HUVEC). 
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As it can be seen in figure 14 we verify that leukemic cell express minimal 
amounts of VEGF-C and VEGFR-3 in comparison with HUVEC. HUVEC express higher 
levels of VEGFR-3 mRNA in comparison with VEGF-C.   
 
 
 
 
 
 
FIGURE 14 – Endothelial cells express higher levels of VEGFR-3. qPCR for VEGF-C and VEGFR-3 mRNA 
expression in leukemic and endothelial cells. mRNA expression is relative to internal control gene 
expression 18S. n=3 
 
Bcl-2 mRNA levels are higher in acute leukemia cells 
 
As referred previously high expression of Bcl-2 is related with malignant cells, so 
next we compare Bcl-2 mRNA expression levels in THP-1 cells with HUVEC by RQ-PCR.  
Bcl-2 mRNA expression is significantly higher in AML cells comparing with 
HUVEC, reinforcing the relevant role of Bcl-2 as an anti apoptotic factor in leukemic cell 
survival. 
  
                                                               
 
 
 
FIGURE 14 – AML cells express higher Bcl-2 mRNA. qPCR for Bcl-2 mRNA expression in leukemic and 
endothelial cells. mRNA expression is relative to internal control gene expression 18S. n=3
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The purpose of this work was to address if cholesterol is a regulator of the expression of 
VEGF-C and its receptor VEGFR-3, in AML cells.  
Cholesterol is an important component of cellular membranes and plays a fundamental 
role in cell signaling (Wymann et. al 2008). Presently its role in hematological malignancies is 
not completely understood neither is its role in tumor angiogenesis mechanisms that 
contribute to disease aggressiveness; nevertheless, many studies including some from our 
Lab point towards cellular cholesterol and plasma cholesterol  involvement in hematological 
cancer progression. In the present work we focused our attention on how may cellular 
cholesterol levels contribute to regulate the production of VEGF-C by leukemic cells. 
Either alone or in conjugation with cholesterol MβCD has been extensively used to study 
cellular modifications cause by the disruption of normal lipid homeostasis of the membrane. 
It is a well-accepted tool to modify the structure and function of the plasma membrane 
(Upadhyay et al. 2006) but it is important to consider the impact that MβCD and MβCD + 
cholesterol complexes have in cell viability. Because of this, for each cell type different times 
of exposure and different concentrations should be tested. Some reports mention that 
under conditions of very low cholesterol, after long exposures to MβCD or high 
concentrations, cells typically lose their morphology which may promote the loss of cell 
viability (Zidovetzki et. al 2007). 
First we investigated how MβCD impacted cell viability in cells and the patterns of 
cholesterol depletion and enrichment in an effort to define our experiments based on an 
approach that positively correlates cell viability with efficient cholesterol alterations in 
cellular membrane.  Both AML cell lines used presented cell susceptibility to MβCD 
concentrations above 1mM and cells treated with higher concentrations show a faster 
viability decrease over time (Figure 5). This  confirms that cell cholesterol depletion with this 
molecule has to be adjusted in terms of exposure and concentration, otherwise cell viability 
is impaired. As 0.2 mM showed to keep cell viability almost constant in time, it was our first 
choice to deplete cholesterol.  MβCD + cholesterol complexes were also used at a low MβCD 
concentrarion (0.2mM) which can explain the maintainance of cell viability for long periods 
of time (Figure 6). Cholesterol concentration of 0.02 mM was efficient in enriching cells with 
cholesterol, which together with an ideal concentration of MβCD proved to be a good 
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mechanism for cholesterol delivery to cells (Figure 4). Based on this data and previously 
identical studies (Casalou et al. 2011), 4 hours of exposure was chosen as the most suitable 
time point for both enrichment and depletion of the cellular cholesterol.  
Changes at the expression levels of a set of genes that regulate cholesterol homeostasis 
are a good marker to address whether cholesterol content changes inside cells. LDLR and 
ABCA1 are key regulators of cellular cholesterol influx and efflux, respectively. When cells 
detect low levels of cholesterol LDLR mRNA expression is activated in order to increase the 
efficiency of cholesterol uptake and when there is cholesterol excess ABCA1 mRNA 
expression is activated in order to increase cholesterol exportation at the membrane. 
Another complex key steps occur in regulation of cholesterol homeostasis but here our goal 
was just to verify if cells are responding as expected to induced cholesterol disruptions. It 
was seen that with 4 hours exposure to the lower concentration of 0.2 mM MβCD, cells 
respond significantly (Figure 8). We assumed then that other changes related with 
cholesterol modulation should be also detected, and 0.2mM MβCD was the concentration 
chosen to perform our experiments.     
One mechanism by which VEGF-C leads to tumor cell survival and resistance to 
chemotherapy is by increasing the expression of the anti-apoptotic gene Bcl-2 (No et al. 
1999) (Dias et al. 2002).  
Here we wanted to assess whether cholesterol was required for the VEGF-C induced 
expression of Bcl-2 in leukemic cells. No differences in Bcl-2 mRNA expression were however 
found when intracellular cholesterol was either depleted or enriched. These results suggest 
that cholesterol levels don’t affect the expression of Bcl-2 at the mRNA level (Figure 9). 
MβCD efficiently removes cholesterol from the plasma membrane and it may also affect 
cholesterol levels in intracellular membranes (Zidovetzki et al. 2007). The anti-apoptotic Bcl-
2 protein is embedded in the nuclear envelope, endoplasmatic reticulum and  outer 
mitochondrial membrane (Youle et al. 2008) and whether MβCD mediated cholesterol 
changes can achieve these sub-cellular locations in order to promote Bcl-2 activity alteration 
was not analyzed. Assuming that the cell function is affected by the variation of cholesterol 
levels Bcl-2 modulation at mRNA level seems to be independent of cholesterol levels. In one 
cell line we did detect a tendency for Bcl-2 to be increased in the presence of MβCD, 
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however this was not stastistically significant (Figure 9B). This may suggest some relationship 
between cholesterol depletion and levels of Bcl-2 expression but either increasing the 
number of samples or the exposure of cells to MβCD will be required to confirm it. We tried 
to assess Bcl-2 protein levels by western blot to confirm these data with no success, maybe 
due to problems with the chosen anti-Bcl-2 antibody (data not shown).  
Some subsets of acute myeloid leukemias express VEGFR-3 and it is assumed that VEGF-
C signaling through this receptor leads to leukemic cell proliferation and survival. It was 
reported that VEGFR-1 expression and signaling is linked to cholesterol levels in acute 
leukemia (Casalou et al. 2011) highlighting the importance of cellular cholesterol levels in 
regulating the VEGF family of proteins, namely in acute leukemia. In the context of our 
study, we assessed if cellular cholesterol levels in the plasmatic membrane are modulating 
VEGFR-3 expression in AML by depletion and enrichment of cholesterol. First, by qPCR a 
decrease in VEGFR-3 mRNA expression was verified with both low and high cholesterol 
conditions in both cell lines that were used with a residual trend to be more sub-expressed 
in cholesterol enriched cellular environment (Figure 10). The fact that increase and decrease 
of intracellular cholesterol content give the same outcome, suggest that either VEGFR-3 
expression is very sensitive to cholesterol changes or the effect seen is not related to 
cholesterol but to any other effect of MβCD. The observations seen at the VEGFR-3 mRNA 
expression levels although do not correspond to our flow cytometry results which points to 
the expression maintenance of VEGFR-3 in both cholesterol conditions although only THP-1 
cell line has been tested for flow cytometry (Figure 13). The discrepancy between the data 
obtained at the mRNA and protein level could be explained by a big stability of the VEGFR-3 
receptor protein. As we chose the same time point to address both mRNA and protein 
expression it is possible that the changes detected at the RNA level had no time to change at 
the protein level.  
VEGFR-1 is known to be located at caveolae cholesterol rich domains in plasma 
membrane in leukemic cells (Casalou et al. 2011) and the presence of VEGFR-3 in these 
caveolae domains has also been reported, but in endothelial cells membrane (Galvagni et al. 
2007), which suggest that VEGFR-3 may also localize at caveolae in leukemic cells. Caveolae 
maintenance is modulated by cholesterol levels in membrane and its disruption may affect 
receptor function and downstream signaling (Frank et al. 2006). It is important as a future 
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approach to address if VEGFR-3 is also located at caveolae in acute leukemia cells because 
cholesterol disruption in lipid rafts could lead to impaired expression of this receptor in case 
of poor amounts or in case of higher amounts of cholesterol, which could suggest a need for 
a strong balance in cholesterol levels for gene expression of VEGFR-3.  
VEGF-C undergoes proteolytic processing in cells forming a set of processed variants 
that are secreted. In this work we were able to detect by western blot two VEGF-C forms of 
different sizes. Both cell lines showed a band of 31 KDa, that may correspond to the 
processed form prior to the mature form, and a band of 21 KDa that may correspond to the 
mature form (Joukov et al. 1997). Depleting cholesterol from cells with MβCD led to an 
increase of VEGF-C mRNA levels which was also observed at protein level by Western Blot in 
both cells lines (Figure 11 and 12). Enrichment of cholesterol content with MβCD + 
cholesterol complexes reduces VEGF-C protein levels in both cell lines, with greater 
significance in THP-1 cell line. This is not observed at mRNA levels, where VEGF-C mRNA 
expression does not change in HEL cell line. In THP-1 cell line there is a tendency to VEGF-C 
mRNA expression increase in higher cholesterol levels however this is not statistically 
significant. Processing mechanisms such as post translational modifications and proteolytic 
processing may be behind these differences between VEGF-C mRNA and protein levels, 
however it seems clear that depletion and enrichment of cholesterol levels with MβCD and 
MβCD cholesterol complexes, respectively, are somehow interfering with VEGF-C production 
in AML cells.  
 In order to investigate the release of VEGF-C, AML cells were treat with 0.2 mM MβCD 
and 0.2 mM + cholesterol complexes during four hours and ELISA assay were performed but 
due to very low amounts of VEGF-C in cell supernatants no consistent results were achieved 
(data not shown), a larger time point and superior cell concentration should be used in 
future experiments.  
Increased VEGF-C production is evident when cells are treated with 0.2 mM MβCD 
which could be related with the decrease in VEGFR-3 mRNA levels. It would be interesting in 
the future to investigate the expression levels of VEGF-D, another VEGF-C receptor. It should 
be noted that all this observations were made with a four hours time point which does not 
invalidate that the low production of VEGFR-3 mRNA will not be reflected later at the 
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membrane level, the same for VEGF-C, whose increases at protein level may be manifested 
more significantly at later time points.  
As a general conclusion our preliminary results suggest that enrichment and depletion 
of cholesterol with 0.2 mM MβCD regulate VEGF-C and VEGFR-3 expression. This work opens 
new questions that need to be explored, namely if the higher production of VEGF-C showed 
here in cholesterol depletion conditions is involved with higher proliferation and survival of 
AML cells, and whether it may be related with an autocrine loop that promotes disease 
promotion. Functional assays with several chemotherapeutic drugs may also be an useful 
approach to test cell resistance and if it is linked to the expression changes verified. It is also 
important to evaluate the effects of the method used here to induce cellular cholesterol 
changes, since MβCD can be interfering with other cellular functions that subsequently 
change VEGF-C and VEGFR-3 expression. Addition of LDL to cell medium may mimic in a 
better way the increase of cellular cholesterol and all the cellular responses related to that. 
Similarly the use of lipoprotein depletion media or HDL may be an alternative way for 
reducing cellular cholesterol levels.  
Taken together, these results do not fully support our initial hypothesis suggesting that 
higher cholesterol levels might be related with higher expression of VEGF-C by AML cells, but 
open new possibilities to be explored in order to understand which mechanisms are behind 
the observations made here and whether these are involved in AML pathogenesis.  
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TABLE S1 – qPCR primer sequences 
PRIMER SEQUENCE  5’ TO 3’ 
HUMAN ABCA1 FWD 
HUMAN ABCA1 RV 
GATCTGGAGGAGCAGTTAGG   
GAGTTGAGGTTGGCCTGTTC 
HUMAN BCL-2 FWD 
HUMAN BCL-2 RV 
TTCTTTGAGTTCGGTGGGGTC 
TGCATATTTGTTTGGGGCAGG 
HUMAN CD36 FWD 
HUMAN CD36 RV 
GGTGTGGTGATGTTTGTTGC 
CAGGGCCTAGGATTTGTTGA 
HUMAN LDLR FWD 
HUMAN LDLR RV 
GATACCAAGGGCGTGAAGAC 
AAGCCATGAACAGGATCCAC 
HUMAN VEGF-C FWD 
HUMAN VEGF-C RV 
GATCTGGAGGAGCAGTTAGG 
GAGTTGAGGTTGGCCTGTTC 
HUMAN VEGFR-3 FWD 
HUMAN  VEGFR-3 RV 
ACCAAACAAGGAGCTGGATG 
ATTTCTGGGGCAGGTTCTTT 
HUMAN 18S FWD 
HUMAN 18S RV 
GCCCTATCAACTTTCGATGGTA 
CCGGAATCGAACCCTGAATT 
HUMAN SRB1 FWD 
HUMAN SRB1 RV 
TCCTCACTTCCTCAACGCTG 
TCCCAGTTTGTCCAATGCC 
 
 
TABLE S2 – Methyl-β-Cyclodextrin + cholesterol 
MβCD 0.5 g 
Cholesterol 0.030 g 
Isopropanol/choloroform (2:1) 200 μl 
1x PBS 5.5 mL 
  
 
TABLE S3 – Methyl-β-Cyclodextrin 
MβCD 0.5 g 
Isopropanol/choloroform (2:1) 200 μl 
1x PBS 5.5 mL 
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TABLE S4 – isopropanol/chloroform (2:1) 
Isopropanol/Chloroform (2:1) 200 μl 
1x PBS 5.5 mL 
 
TABLE S5 – RIPA buffer 
Tris 50 mM pH 7.4 500 μl 
NaCl 150 mM 300 μl 
EDTA 5mM 100 μl 
NP-40 1% 100 μl 
SDS 0.1% 10 μl 
Sodium deoxycholate 0.5% 0.05 g 
Na3VO4 1 mM 20 μl 
1mM NaF10 mM 20 μl 
H2O 10 mL 
 
TABLE S5 – 5x Laemli Buffer  
Tris-Base 500 mM 2 mL 
Bromophenol Blue 4 mL 
Glycerol 2 mL 
SD 10% 0.2g 
 
TABLE S6 – 10% poly-acrilamide gel 
Acrylamide 30% 2.1 mL 
Tris 1.5 M pH 8.8 2.7 mL 
10% SDS 80 μl 
10% APS 40 μl 
TEMED 4 μl 
H2O 3.2 mL 
 
TABLE S7 – stacking Gel 
Acrylamide 30% 0.35 mL 
Tris 0.5M pH 6.8 0.75 mL 
SDS 10% 30 μl 
APS 10% 30 μl 
TEMED 3 μl 
H2O 1.84 mL 
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TABLE S8 – Running Buffer 10x 
Tris 25mM 0.30 g 
Glycine 190mM 14.2 g 
H2O 1 L (Adjust pH 8.3) 
 
TABLE S9 - Running Buffer 1x 
Running Buffer 1x 100 mL 
SDS 0.1% 1 mL 
H2O 900 mL 
 
 
TABLE S10 – Transfer Buffer 10x 
Tris 250 mM 30.2 g 
1250 mM 93.83 g 
H2O 1 L 
 
 
TABLE S11 – Transfer Buffer 1x 
Transfer Buffer 1x 100mL 
Methanol 100 mL 
H2O 800 mL 
 
 
TABLE S12 – 10x TBS 
Trizma HCl 24.23 g 
NaCl 80.06 g 
H2O 1 L (AdjustpH 7.6) 
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Table S12 – 1x TBS-T (Tween-20) 
TBS 10x 100 mL 
H2O 900 mL 
Tween-20 1 mL  
 
 
Table S13 – PBS/BSA  
PBS 1x 100 mL 
BSA 1% 0.5 g 
 
